NL-OMON44409已完成不适用
Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis - Effect of fingolimod on brain and cognition
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Subjects should be between 18 and 65 years of age
- •- Subjects should meet the safety criteria to undergo MRI examination
- •- Patients should be diagnosed with RRMS
- •- The first measurement of patients on fingolimod should be within four weeks after the start of fingolimod treatment
排除标准
- •- Presence or history of psychiatric or neurological disease (for patients: neurological disease other than MS) that is expected to affect outcome measures (will be discussed with the principal investigator and neurologist)
- •- Presence or history of drug abuse
- •- For patients: relapse or steroid treatment less than four weeks prior to examination
- •- Insufficient visual acuity and motor skills to perform the fMRI task
研究者
相似试验
尚未招募
不适用
Effects of fingolimod on advanced brain measures and clinical measures in multiple sclerosismultiple sclerosis, functional magnetic resonance imaging, cognition, functional brain adaptationmultiple sclerose, functionele MRI, cognitie, functionele brein adaptatieNL-OMON24446VU University Medical Center70
进行中（未招募）
不适用
Effects of fingolimod on advanced brain measures and clinical measures in multiple sclerosisEUCTR2014-001012-19-NLVU University Medical Center
招募中
2 期
The efficacy of fingolimod in enhancing recovery after traumatic spinal cord injuryspinal cord injury.Injury, poisoning and certain other consequences of external causesT09.3IRCT20240701062291N1Mashhad University of Medical Sciences36
进行中（未招募）
1 期
Effect of fingolimod on cardiac autonomic regulation in MS-patientsMedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disordersMultiple sclerosisEUCTR2012-002694-66-FISakari Simula30
终止
4 期
Effect of Fingolimod on NeurodegenerationCognitionBrain Volume LossNCT02575365Novartis Pharmaceuticals4